A Non-Interventional Observational Study Evaluating The Effects Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy On Safety In Postmenopausal And Hormone Receptors Positive Early Breast Cancer Patients
This study was terminated on 01-Aug-2011 due to very low potential to enroll planned number
of patients or any sufficient number of patients for complete statistical analyses. This
study is not being terminated because of safety or efficacy concerns.
Observational Model: Case Control, Time Perspective: Prospective
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence attributed to study medication in a participant who received study medication.
Month 0 up to Month 36 or early withdrawal
Pfizer CT.gov Call Center
Russia: Central Ethic Committee